Reaching Mass Production | Tianma Pluidic panel-level microfluidic promotes rapid development of biochip industry
With many emerging technologies such as IoT, AI and 5G coming one after another, the sensor field has witnessed rapid development.However, the current situation of diversified demand, long development cycle, high cost and insufficient production capacity makes the traditional sensor development model face severe challenges. Relying on its muscular R&D strength in TFT technology and flexible and diversified manufacturing capabilities, Tianma has completed many forward-looking technology developments in biomedical, intelligent transportation, artificial intelligence, information and communication, etc. It has opened up a new field of high-precision manufacturing for the panel manufacturing industry and a new sensor industrialization, The advancement route.
In the biomedical field, Microfluidics technology uses precise manipulation of microscopic liquids to integrate complex experimental steps such as sample processing, reaction, detection, and analysis on a biochip, which is the core technology of Lab-on-chips. Microfluidics is regarded as a revolutionary technology for future biotechnology, which can be widely used in various biochemical assays, such as clinical diagnosis, gene sequencing, immunoassay, single cell analysis, etc. It can reduce the analysis time, reagent usage and labour input through integrated high-throughput assays, thus replacing traditional biochemical experimental equipment and labour.
However, the development of the microfluidic chip industry chain needs to be more mature. The traditional manufacturing technology is challenging to realize the mass production of high-throughput, high-precision, low-cost chips. The related technology is mainly in the laboratory stage, far from the large-scale market application. For this reason, Tianma has successfully developed the Panel-Level-Microfluidics (Pluidic) technology, which can provide customized design and mass production services for glass-based microfluidic chips with various process routes and extensively promoting the industrialization of microfluidic technology by combining the mature manufacturing process of industry-leading display panels.
Microfluidics can be broadly divided into continuous microfluidics, which manipulates continuous fluids based on microfluidic channels, and digital microfluidics, which uses independent microdroplets based on principles such as dielectric wetting.
Tianma has developed a continuous microfluidic chip based on the glass etched flow channel method to realize the demand for high-precision glass microfluidic chip manufacturing. With many advantages such as high throughput, high precision, low cost and customizable experiments, Tianma's continuous microfluidic chips have been shipped for commercial projects in fields such as gene sequencing.
In terms of digital microfluidics, Tianma has successfully developed active digital microfluidic chips based on various TFT technologies such as a-Si/Oxide/LTPS, as well as single-layer/multi-layer electrode passive digital microfluidic chips, with a variety of process routes and design solutions to meet the functional requirements of different applications. We have started commercial projects with many customers in PCR amplification, gene library, immunoassay, and single-cell analysis. The a-Si solution, for example, can flexibly and independently control thousands of 100-micron drive electrodes and drive pL~uL droplets in batches using the active method, which has the advantages of high precision, high throughput, low cost, programmability and portability.
In the future, Tianma will further improve the performance and mass production capability of panel-level microfluidic products, realize the integration of multiple types of related sensing functions, complete the development of microfluidic products with more technical solutions, and provide customers with better microfluidic product solutions and production services.
Tianma also provides its unique MPG (Multi-Project-Glass) technology platform for microfluidics and other emerging technologies, which can give mature a-Si, LTPS, IGZO and LTPO backplanes for innovative companies, universities and research institutes and conduct pre-development and transformation of related technologies and products, helping to implement associated technologies.
As an essential part of the "N" in the company's "2+1+N" strategy, the company is committed to providing the most advanced products and services in biomedical, intelligent transportation, and artificial technology. In non-display fields such as bio-medical, smart transit, artificial intelligence, information and communication, Tianma will continue to develop technology and products and work with customers to promote mass production and incubation in related industries.
From：https://www.tianma.cn/2022111111/39072.jhtml
